Corpus ID: 18648350

Extending the TITE CRM to Multiple Outcomes with Application to a Phase 1 Clinical Trial in Canine Hemangiosarcoma

@inproceedings{Koopmeiners2012ExtendingTT,
  title={Extending the TITE CRM to Multiple Outcomes with Application to a Phase 1 Clinical Trial in Canine Hemangiosarcoma},
  author={J. Koopmeiners and J. Modiano},
  year={2012}
}
In traditional phase 1 oncology trials, the safety of a new chemotherapeutic agent is tested in a dose escalation study to identify the maximum tolerated dose, which is defined as the highest dose with acceptable toxicity. An alternate approach is to jointly model toxicity and efficacy and allow dose finding to be directed by a pre-specified trade-off between efficacy and toxicity. With this goal in mind, several phase 1 designs have been proposed to jointly model toxicity and efficacy in phase… Expand

References

SHOWING 1-10 OF 16 REFERENCES
An adaptive dose-finding design incorporating both toxicity and efficacy.
  • 144
Sequential designs for phase I clinical trials with late-onset toxicities.
  • 372
  • Highly Influential
  • PDF
Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
  • 124
  • PDF
Bayesian dose finding by jointly modelling toxicity and efficacy as time-to-event outcomes
  • 71
Dose-finding based on efficacy-toxicity trade-offs.
  • 353
  • Highly Influential
  • PDF
Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.
  • 104
  • PDF
Continual reassessment method: a practical design for phase 1 clinical trials in cancer.
  • 1,203
Design and analysis of phase I clinical trials.
  • 685
...
1
2
...